2022
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidance
2017
The Role of Robotics in the Invasive Management of Bladder Cancer
Khetrapal P, Tan W, Lamb B, Tan M, Baker H, Thompson J, Sridhar A, Kelly J, Briggs T. The Role of Robotics in the Invasive Management of Bladder Cancer. Current Urology Reports 2017, 18: 57. PMID: 28634646, DOI: 10.1007/s11934-017-0706-7.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyRobot-assisted laparoscopic prostatectomyRadical cystectomyUrinary reconstructionIntracorporeal robot-assisted radical cystectomyManagement of bladder cancerOpen radical cystectomySurgical learning curveBladder cancer surgeryEnhanced recovery programmeComparison of outcomesLaparoscopic prostatectomyOncological outcomesIleus ratesBladder cancerCancer surgeryPerioperative measuresOpen techniqueInvasive managementShort recovery periodRobotic approachImprove outcomesPatient outcomesReduce recovery timeCystectomy